Tirzepatide: Dual GIP/GLP-1 Receptor Agonist Research

Tirzepatide (LY3298176) is an investigational peptide developed by Eli Lilly that functions as a dual agonist at two incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Built on a modified GIP peptide backbone with GLP-1 receptor-activating properties engineered in, tirzepatide represented a mechanistic departure from single-receptor GLP-1 agonists at the time of its development, and its Phase 3 research programme produced some of the largest reported weight-reduction effects for an incretin-based compound prior to the emergence of triple agonists such as retatrutide.

Understanding the Dual Agonist Mechanism

Tirzepatide's design reflects a specific research hypothesis: that combining GIP and GLP-1 receptor activation in a single molecule would produce additive or synergistic metabolic effects beyond what either pathway achieves alone.

GIP Receptor Agonism

Glucose-dependent insulinotropic polypeptide (GIP) is secreted from intestinal K-cells following nutrient intake. Historically, GIP's role in obesity research was debated, since GIP receptor signalling was originally associated with fat storage in some models. However, tirzepatide's research programme, along with related preclinical work, indicated that pharmacological (rather than physiological) GIP receptor agonism — particularly in the context of simultaneous GLP-1R activation — produces a net weight-reducing effect, potentiating satiety signalling and improving the tolerability of the GLP-1 component by reducing nausea.

GLP-1 Receptor Agonism

The GLP-1 receptor component of tirzepatide's activity mirrors the mechanism of single-agonist compounds like semaglutide: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction via hypothalamic and brainstem signalling. Tirzepatide's GLP-1R binding affinity was deliberately engineered to be lower than that of native GLP-1 or semaglutide, a design choice researchers have proposed may broaden its therapeutic window by moderating GLP-1-driven gastrointestinal side effects while preserving efficacy.

Clinical Research Findings

The SURMOUNT clinical trial programme evaluated tirzepatide in adults with obesity across multiple study populations. Key findings from SURMOUNT-1 (published in the New England Journal of Medicine, 2022) included:

• Mean weight reduction of approximately 15–20.9% from baseline across dose groups (5mg, 10mg, 15mg) over 72 weeks, with the highest dose group showing the greatest effect
• A substantial proportion of participants achieved ≥20% weight reduction at the highest studied dose, a threshold rarely reported in prior incretin research
• Improvements in cardiometabolic markers including blood pressure, waist circumference, and lipid parameters
• Improved glycaemic control, with tirzepatide also separately studied in type 2 diabetes populations (the SURPASS trial programme) showing meaningful HbA1c reductions

Subsequent research, including the SURMOUNT-OSA studies, has extended investigation of tirzepatide's mechanism into obstructive sleep apnoea and other obesity-associated comorbidities, reflecting the broader research interest in downstream effects of substantial pharmacological weight reduction.

Preclinical Research

Preclinical characterisation of tirzepatide in rodent and non-human primate models demonstrated dose-dependent reductions in body weight and food intake exceeding those observed with GLP-1R-selective comparators at matched receptor occupancy. Mechanistic studies using GIPR knockout models have been used to isolate the contribution of each receptor pathway, supporting the hypothesis that GIPR co-agonism potentiates rather than merely adds to GLP-1R-driven effects.

Research Context: Tirzepatide and Related Compounds

Tirzepatide's dual-receptor mechanism sits between single-agonist compounds like semaglutide and triple-agonist compounds like retatrutide, which adds glucagon receptor agonism on top of the same GIP/GLP-1 foundation. For a detailed mechanistic and trial-data comparison between tirzepatide and retatrutide, see our Tirzepatide vs Retatrutide article, and for broader context on the GLP-1 receptor agonist research class, see our GLP-1 peptides Malaysia guide.

Conclusion

Tirzepatide's dual GIP/GLP-1 receptor mechanism established a new benchmark for incretin-based metabolic research, demonstrating that expanding beyond single-receptor targeting could produce substantially greater weight-reduction effects while maintaining a manageable tolerability profile. Its extensive Phase 3 research programme, spanning obesity, type 2 diabetes, and downstream comorbidities, has made it one of the most thoroughly characterised compounds in modern metabolic peptide research. Malaysian researchers interested in sourcing this compound can refer to our guide on how to buy Tirzepatide in Malaysia.